Uncategorized

High Dose Oral Steroids in Sudden Sensorineural Hearing Loss

March 10, 2021

CATEGORY:
Clinical Trials

TITLE:
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss

INTERVENTION/TREATMENT:

PHASE:

DESCRIPTION:
Condition : Sudden Sensorineural Hearing Loss (SSNHL)

Interventions : Drug: Dexamethasone; Drug: Prednisone

Sponsor : University of Colorado, Denver

Recruiting

ID:
NCT03255473

STATUS:

DATE – FIRST POSTED:
Mon, 21 Aug 2017 12:00:00 EDT

DATE – LAST UPDATE POSTED:
03/10/21 06:35AM

DATE – RETRIEVED:
03/10/21 06:35AM

LINK – STUDY HISTORY:
https://clinicaltrials.gov/ct2/history/NCT03255473

LINK – STUDY RECORD:
https://clinicaltrials.gov/ct2/show/NCT03255473

Promise of Optogenetics ‘Sheds Light’ on Hearing Restoration

February 26, 2021

https://journals.lww.com/thehearingjournal/Fulltext/2021/03000/Promise_of_Optogenetics__Sheds_Light__on_Hearing.1.aspx

Promise of Optogenetics ‘Sheds Light’ on Hearing Restoration
Glantz, Gordon

The Hearing Journal: March 2021 – Volume 74 – Issue 3 – p 20,22,23
doi: 10.1097/01.HJ.0000737552.03771.a4

Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning… to help lead pre-commercial strategy and launch planning for FX-322 (and its potential commercialization both in the US and internationally)…

February 8, 2021

https://www.businesswire.com/news/home/20210208005168/en/Frequency-Therapeutics-Appoints-Kevin-Franck-Ph.D.-as-Senior-Vice-President-Strategic-Marketing-and-New-Product-Planning

Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning… to help lead pre-commercial strategy and launch planning for FX-322 and for potential commercialization in the US…

Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning
Dr. Franck joins from Massachusetts Eye and Ear, where he was Director of Audiology and Harvard Medical School Faculty in the Department of Otolaryngology-Head and Neck Surgery

February 08, 2021 07:00 AM Eastern Standard Time
WOBURN, Mass.–(BUSINESS WIRE)–Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Kevin Franck, Ph.D., as Senior Vice President of Strategic Marketing and New Product Planning. Dr. Franck will lead pre-commercial strategy and launch planning for Frequency’s clinical pipeline, including its lead program aimed at developing a restorative treatment for sensorineural hearing loss (SNHL), the most common form of hearing loss.

Baicalin attenuates gentamicin-induced cochlear hair cell ototoxicity

April 25, 2019

https://onlinelibrary.wiley.com/doi/abs/10.1002/jat.3806

https://www.ncbi.nlm.nih.gov/pubmed/31021006?dopt=Abstract

Baicalin attenuates gentamicin-induced cochlear hair cell ototoxicity.

J Appl Toxicol. 2019 Apr 25;:

Authors: Zhang X, Yu J

Abstract

Gentamicin can lead to cochlear hair cells associated ototoxicity by inducing apoptosis and oxidative stress, which can be alleviated by baicalin, one flavonoid extracted from the root of Scutellaria baicalensis. The role of baicalin in protecting gentamicin-induced hearing loss is unclear. Interference with oxidative stress was investigated in this study using House Ear Institute-Organ of Corti1 (HEI-OC1) cells, which were simultaneously treated with baicalin (0-400 μm) and gentamicin (0.2 or 1 mm). MTT was used to assay cell viability and apoptosis was detected with Annexin V-fluorescein isothiocyanate staining. The production of reactive oxygen species was indicated by 2,7-dichlorofluorescein diacetate fluorescence intensity and mitochondrial depolarization was assayed by JC1-mitochondrial membrane potential assay. Poly(ADP-ribose) polymerase (PARP), cleaved-caspase 3 and cleaved-PARP expression were analyzed with western blot. Baicalin improved the viability of HEI-OC1 cells and significantly reduced the oxidative stress and mitochondrial depolarization compared with the gentamicin treatment group. Gentamicin treatment increased the activation of PARP and caspase-3, while such an increase could be downregulated by baicalin. Baicalin attenuates gentamicin-induced cochlear hair cells ototoxicity, and such inhibition may be mediated by the regulation of reactive oxygen species production, mitochondrial depolarization, and caspase-3 and PARP activation.

PMID: 31021006 [PubMed – as supplied by publisher]

Supporting cell survival after cochlear implant surgery

October 16, 2018

https://onlinelibrary.wiley.com/doi/abs/10.1002/lary.27539

https://www.ncbi.nlm.nih.gov/pubmed/30325510?dopt=Abstract

Supporting cell survival after cochlear implant surgery.

Laryngoscope. 2019 01;129(1):E36-E40

Authors: deTorres A, Olszewski RT, Lopez IA, Ishiyama A, Linthicum FH, Hoa M

Abstract

Supporting cells (SCs) provide structure and maintain an environment that allows hair cells to receive and transmit signals in the auditory pathway. After insult to hair cells and ganglion cells, SCs respond by marking unsalvageable cells for death and maintain structural integrity. Although the histopathology after cochlear implantation has been described regarding hair cells and neural structures, surviving SCs in the implanted ear have not. We present a patient whose posthumous examination of an implanted cochlea demonstrated SC survival. This finding has implications for SC function in maintaining electrical hearing and candidacy for future hair cell regeneration therapies. Laryngoscope, 129:E36-E40, 2019.

PMID: 30325510 [PubMed – indexed for MEDLINE]